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The development of whole exome/genome sequencing technologies has given rise to an unprecedented
volume of data linking patient genomic variability to brain disorder phenotypes. A surprising number of
variants have been found in the N-methyl-D-aspartate receptor (NMDAR) gene family, with the GRIN2B
gene encoding the GluN2B subunit being implicated in many cases of neurodevelopmental disorders,
which are psychiatric conditions originating in childhood and include language, motor, and learning
disorders, autism spectrum disorder (ASD), attention deﬁcit hyperactivity disorder (ADHD), develop-
mental delay, epilepsy, and schizophrenia. The GRIN2B gene plays a crucial role in normal neuronal
development and is important for learning and memory. Mutations in human GRIN2B were distributed
throughout the entire gene in a number of patients with various neuropsychiatric and developmental
disorders. Studies that provide functional analysis of variants are still lacking, however current analysis of
de novo variants that segregate with disease cases such as intellectual disability, developmental delay,
ASD or epileptic encephalopathies reveal altered NMDAR function. Here, we summarize the current
reports of disease-associated variants in GRIN2B from patients with multiple neurodevelopmental dis-
orders, and discuss implications, highlighting the importance of functional analysis and precision
medicine therapies.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
N-methyl-D-aspartate receptors (NMDARs) are a family of ion-
otropic glutamate receptors that mediate a slow, Ca2þ permeable
component of excitatory synaptic transmission in the central ner-
vous system (CNS). NMDARs are a tetrameric assembly of two
glycine-binding GluN1 subunits and two glutamate-binding GluN2
subunits. The GluN1 subunit is expressed throughout the CNS,
whereas the four subtypes of GluN2 (AeD) subunits have differ-
ential temporal and spatial expression patterns (1,2). The GluN2B
subunit encoded by GRIN2B is highly expressed prenatally, and its
expression level starts to decline after birth in most brain regionsgy, Emory University School
ad, Atlanta, GA 30322, USA.
).
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g by Elsevier B.V. on behalf of Japa
d/4.0/).(1). The early expression of this NMDAR subunit suggests it may
play an important role in brain development, circuit formation, and
perhaps cellular migration and differentiation, as well as synaptic
plasticity (3). GluN2B expression dominates during rapid cortical
synaptogenesis in late embryogenesis and early postnatal devel-
opment (4). Neonate lethality of GRIN2B knock-out mice was
observed (5), while overexpression of GRIN2B in the forebrain of
mice enhanced hippocampal long-term potentiation and spatial
memory performance (6).
In light of the important role of GRIN2B in controlling NMDAR
function, the time course of synaptic currents and plasticity,
mutation-related disruption in the GluN2B subunit expression or
function might give rise to a number of neurodevelopmental phe-
notypes that reﬂect alterations in circuit formation, neuronal con-
nectivity, synaptic plasticity, and excitatory transmission. Since the
identiﬁcation of the ﬁrst disease-causing mutations in NMDARs
(7,8) over 60 variants in the GRIN2B have been reported in the
literature identiﬁed in individuals from patient cohorts with a
number of neurodevelopmental disorders, including intellectual
disability (ID), developmental delay (DD), autism spectrumnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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and to a lesser extent attention deﬁcit hyperactivity disorder
(ADHD), cerebral visual impairment (CVI), and Alzheimer's disease
(AD) (Fig. 1 and Table 1). We expect the discovery of additional rare
GRIN2B genetic variants and de novo mutations to grow as more
clinics utilize exome sequencing as a tool in diagnostic programs to
better understand the molecular basis for neurodevelopmental
disorder(s) in pediatric patient populations. GRIN2B variants and de
novo nonsynonymous mutations with neurological disease has
recently been reviewed (55,56). Here we review all missense,
nonsense, frameshift, or splice site GRIN2B mutations identiﬁed in
individuals from patient cohorts with deﬁned neurodevelopmental
and psychiatric disorders such as ID and DD (7,9e15,17,18,21,29,54),
EE (7,13,15,16,53,54), ASD (18e20,22e26,54), SCZ (19,20,26,27), AD
(28), and CVI (11). The GRIN2B variants identiﬁed thus far occurred
throughout the entire NMDAR subunit protein. That is, variants
were found in the amino-terminal domain (ATD), agonist-binding
domain (ABD), transmembrane domain (TM), and carboxyl-
terminal domain (CTD) (Fig. 1). In spite of the increasing number
of reports of new GRIN2B variants due to the recent advances of
next-generation sequencing technologies, studies that provide
thorough functional analyses of the effects of disease-causing
mutations on NMDARs are still lacking. Such functional informa-
tion is central to understanding the pathogenicity of these de novo
mutations and rare variants, and thus is an important priority in
future genetic studies. Here, we provide a domain-speciﬁc review
of GRIN2B variants revealing that rare de novomutations in the ABD
and TM domains, but not the ATD and CTD domains, are absent in
the exomes of a large control population sample (Table 1; 35).
Furthermore, many of these ABD and TM rare variants result in
signiﬁcant alteration of NMDA receptor channel properties
(7,13,16,24,34,54).Fig. 1. Locations of GluN2B mutations. Ribbon structures of a tetramer GluN1/GluN2B rece
The amino terminal domain (ATD) is shown, the S1 and S2 regions describe two portions
transmembrane helices (M1, M3, M4) and the M2 re-entrant pore loop comprise the trans
MAGENTA, transmitted mutations in BLUE, and variants of unknown origin in ORANGE. B,
absent from ExAC are highlighted in CYAN. In both panels an (*) indicates that the variant res
resolution of crystal structure in this region. The variants V18 in the signal peptide, and Q1
S1452 in the carboxyl terminal domain (CTD) are not present in the crystal structure and t2. GRIN2B mutations with chromosome translocation
Chromosome translocation involves rearrangement of parts
between non-homologous chromosomes. To date, two male sub-
jects with de novo chromosome translocations in the GRIN2B gene
have been reported: t(9;12)(p23;p13.1) and t(10;12)(q21;p13.1) (7).
Fluorescence in situ hybridization (FISH) studies also found break-
points in 12p13.1 in both translocations, disrupting the GRIN2B
gene. Both subjects demonstrated moderate to severe mental
disability, behavioral anomalies, and abnormal electroencephalo-
gram (EEG). The 12-year-old subject also had other manifestations
such as microcephaly and eye anomalies. Further, a de novo chro-
mosome inversion (inv(12)(p13.1q21.31)) and three microdeletions
with breakpoints in exon 1 or exon 2 of GRIN2B were identiﬁed in
four patients with similar ID and DD symptoms (7,18,29,30). Thus,
the GRIN2B gene seems to be critical for neuronal development, and
translocation disruption in GRIN2B could lead to pronounced
cognitive phenotypes. More importantly, functional studies on
GRIN2B translocations are needed, since disruption in the GRIN2B
gene might lead to receptor trafﬁcking defects, NMDAR hypo-
function, and alteration of endogenous modulator afﬁnities. Inter-
estingly, a translocation disrupting the GRIN2A gene
(t(16;17)(p13.2;q11.2)), which encodes the GluN2A subunit, was
also associated with severe mental disability and seizures in a 26-
year-old male subject. This same translocation was identiﬁed in 3
similarly affected relatives (7). Further, a microdeletion encom-
passing the GRIN2A gene (16p13.2p13.13) was identiﬁed in three
patients with variable mild to severe intellectual disability and
seizures (8) and overlapping duplications of chromosome 12p
points towards GRIN2B in a series of patients with a variable DD and
ID phenotype (31). Thus, a comparative analysis of GRIN trans-
locations and microdeletions could be informative.ptor (37,38) illustrates receptor architecture (light yellow: GluN1; light blue: GluN2B).
of the polypeptide chain that comprise the agonist binding domain (ABD), and three
membrane domain (TM). A, Residues harboring de novo mutations are highlighted in
Residues harboring mutations in human patients with a clear disease segregation or
ults in a truncated protein. The residue alanine at position 590 is not shown due to poor
014, G1026, R1099, T1228, A1267, T1273, K1293, M1331, M1339, N1352, S1415, L1424,
herefore not shown.
Table 1
GRIN2B subunit variants identiﬁed in neurodevelopmental disorders.
Varianta Genotype Domainb Originc Phenotyped Functional validatione Refs. ExACf #, MAF ClinVar signiﬁcance,
phenotypeg
p.Val18Ile c.52G>A ATD Transh SCZ 26 7, 0.0059% Uncertain, NS
p.Ser34GlnfsX25 c.99dupC ATD DN ASD, ID 24 27, 0.0223% Pathogenic, MR
p.Ile50Asn c.149T>A ATD Transh SCZ 26
p.Val65Ile c.193G>A ATD Trans SCZ* 27 1, 0.0008%
c.411 þ 1 G>A (splice) c.411 þ 1 G>A ATD DN ID 7
p.Ile150Val c.448A>G ATD 54
p.Ala271Val c.812C>T ATD Trans SCZ* 26,27 34, 0.0280%
p.Thr268SfsX15 c.803_804delCA ATD DN ID, ADHD 7,29 Pathogenic, MR
p.Leu362Met c.1084C>A ATD Transh SCZ 26
p.Glu413Gly c.1238A>G ABD (S1) DN ID [ Glu EC50, Y tw, Y expression 34,54 Pathogenic, MR
p.Cys436Arg c.1306T>C ABD (S1) DN ID Y expression 54
p.Cys456Tyr c.1367G>A ABD (S1) DN ASD, ID Y Glu EC50, [ Gly EC50, Y
expression
24,54 Pathogenic, MR
p.Cys461Phe c.1382G>T ABD (S1) DN ID, ASD, Epi [ Glu EC50, Y Gly EC50, Y
tw, Y expression
16,54
p.Asp524Asn c.1570G>A ABD (S1) DN ID 12
p.Arg540His c.1619G>A ABD (S1) DN ID, Epi Y Glu EC50, Y Gly EC50, [
tw, Y expression, [ Mg2þ IC50
13,54 Pathogenic, EE
p.Pro553Leu c.1658C>T linker DN ID 9 Pathogenic, MR
p.Val558Ile c.1672G>A M1 DN ID 12
p.Trp559X c.1677G>A M1 DN ASD, ID 24 Pathogenic, MR
p.Ala590Thr c.1768G>A linker Trans ID 7 19, 0.0157% Uncertain, NS
p.Trp607Cys c.1821G>T M2 DD, ID 21
p.Gly611Val c.1832G>T M2 54 Likely pathogenic, NS
p.Asn615Ile c.1844A>T M2 DN ID, West [ Mg2þ IC50 13 Pathogenic, EE
p.Val618Gly c.1853T>G M2 DN ID, West [ Mg2þ IC50 13 Pathogenic, EE
p.Val620Met c.1858G>A M2 54 Likely pathogenic, EE
p.Ser628Phe c.1883C>T linker DN ID, DD 17
p.Ala636Pro c.1906G>C M3 DN ID, ADHD 29
p.Ala636Val c.1907C>T M3 54 Likely pathogenic, NS
p.Ala639Val c.1916C>T M3 54 Pathogenic, IGD
p.Gln662Pro c.1985A>C ABD (S2) DN ID, Epi 15
p.Phe671_Gln672del c.2011-5_
2011-4delTC
ABD (S2) Trans ID, Epi 13
p.Arg682Cys c.2044C>T ABD (S2) DN ID Y Glu EC50, Y Gly EC50, [ tw 7,29,54 Pathogenic, MR
p.Thr685Pro c.2053A>C ABD (S2) DN 54 Pathogenic, EE
p.Pro687Leu c.2060C>T ABD (S2) 54 Likely pathogenic, NS
p.Pro687Arg c.2060C>G ABD (S2) DN ID, DD 17
p.Gly689Ser c.2065G>A ABD (S2) DN CVI, ID 11 Likely pathogenic, MR
p.Arg696His c.2087G>A ABD (S2) DN ID, DD, ASD Y Glu EC50, [ tw, Y expression 54
p.Met706Val c.2116A>G ABD (S2) DN ID 12
p.Gln711X c.2131C>T ABD (S2) DN ASD 20
c.2172-2A>G (splice) c.2172-2A>G ABD (S2) DN ASD, ID 23,24 Pathogenic, MR
c.2351-2A>G (splice) c.2351-2A>G ABD (S2) DN ASD, ID 23
c.2360-2A>G (splice) c.2360-2A>G ABD (S2) DN ID 7
p.Glu807Lys c.2419G>A linker DN ID, DD 17
p.Ser810Arg c.2430C>A linker 54 Pathogenic, NS
p.Gly820Glu c.2459G>A M4 DN ID 10
p.Gly820Ala c.2459G>C M4 DN ID, DD 17 Conﬂicting interpretations
p.Gly820Val c.2459G>T M4 54 Likely pathogenic, NS
p.Met824Arg c.2471T>G M4 DN ID, DD, Epi 53
p.Leu825Val c.2473T>G M4 DN ASD 19,26
p.Gln1014Arg c.3041A>G CTD Transh SCZ 26
p.Gly1026Ser c.3076G>A CTD Trans ASD, SCZ* 26,27 30, 0.0247% Uncertain, NS
p.Arg1099AlafsX51 c.3295del CTD DN ID 14
p.Thr1228Met c.3683C>T CTD ASD 25 3, 0.0033%
p.Ala1267Ser c.3799G>T CTD Trans ID, SCZ* 7,27 40, 0.0330% Uncertain, NS
p.Thr1273Lys c.3818C>A CTD Trans ASD* 25 52, 0.0429% Uncertain, NS
p.Lys1293Arg c.3878A>G CTD DN AD 28 1, 0.0008%
p.Met1331Ile c.3993G>A CTD ID 7 6, 0.0049%
p.Met1339Val c.4015A>G CTD Trans ASD* 25
p.Asn1352del c.4056_
4058delCAA
CTD Transh SCZ 26 1, 0.0008%
p.Ser1415Leu c.4244C>T CTD Transh ASD 26 1, 0.0008%
p.Leu1424Phe c.4270C>T CTD Transh SCZ 26 3, 0.0025%
p.Ser1452Phe c.4355C>T CTD Transh SCZ 26 2, 0.0016% Uncertain, NS
(continued on next page)
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Table 1 (continued )
Varianta Genotype Domainb Originc Phenotyped Functional validatione Refs. ExACf #, MAF ClinVar signiﬁcance,
phenotypeg
chr translocation t(9;12)(p23;p13) e DN ID, ADHD 7,29
chr translocation t(10;12)(q21;p13) e DN ID, ADHD 7,29
chr inversion inv(12)
(p13.1q21.31)
e DN ID, ASD, Epi 18
chr microdeletion 12p13.1 exon 1-2 DN ID, DD, Epi 30
chr duplication Multiple
12p variants
e DN, Trans DD, ID 31
a fs: frameshift, splice: donor or acceptor splice site, X: termination codon, del: deletion, chr: chromosome.
b ATD: amino terminal domain, ABD: agonist binding domain (S1) and (S2), M1, M2, M3, and M4: membrane-associated domains, CTD: carboxyl terminal domain.
c DN: de novo mutation, Trans: transmitted from parent.
d ID: Intellectual Disability, DD: Developmental Delay, AD: Alzheimer's Disease, ASD: Autism Spectrum Disorder, ADHD: Attention Deﬁcit Hyperactivity Disorder, SCZ:
Schizophrenia or Schizoaffective Disorder, Epi: epilepsy and/or seizures, infantile spasms, CVI: Cerebral Visual Impairment, WEST: West syndrome, * indicates the disorder
phenotype was not present in the transmitting parent.
e Glu, glutamate; Gly, Glycine; upward, downward arrows indicate increase or decrease in measured value, respectively; tw, deactivation rates determined by ﬁtting a two-
component exponential function to determine a weighted tau (tw).
f ExAC dataset of 60,706 control exomes, release 0.3.1 March 2016; MAF ¼ minor allele frequency.
g www.ncbi.nlm.nih.gov/clinvar; Access date 28 Aug 2016; MR ¼ Mental retardation; EE ¼ Epileptic encephalopathy; IGD ¼ Inborn Genetic Disease; NS ¼ Not Speciﬁed.
ClinVar and ExAC only reported when entries were present; for EXaC, no entry suggests MAF <0.0008%.
h Transmission status by personal communication with the group of Dr. Guy A. Rouleau.
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The GluN2B ATD is a clamshell-like structure that harbors the
binding site for the negative allosteric modulator Zn2þ. The GluN2B
ATD also forms a heterodimer with the GluN1 ATD, the interface of
which comprises a binding site for the negative allosteric modu-
lator ifenprodil (32). Three de novo variants have been reported in
the GRIN2B ATD region from patients with intellectual disability.
Interestingly, all three variants are frameshift or splice site muta-
tions leading to premature chain termination of GRIN2B transcripts
and likely haploinsufﬁciency. Speciﬁcally, the ﬁrst two de novo
mutations involving frameshift in GRIN2B ATD were reported in
Endele et al., 2010 (7), both patients had intellectual disability and
behavioral anomalies. A 13-year-old female patient had a hetero-
zygous nucleotide change of c.803_804delCA leading to an altered,
p.Thr268SfsX15, GluN2B protein. A male patient also had a het-
erozygous mutation, c.411þ1G>A, and presented with additional
symptoms of microcephaly, EEG anomalies, and eye anomalies. The
third variant in the GRIN2B ATD, p.Ser34GlnfsX25, reported in a
patient with autism and intellectual disability, was an insertion of a
single nucleotide in the gene leading to a frameshift mutation and
early termination of the protein open reading frame (24). Five
additional nonsynonymous ATD variants were identiﬁed in patient
cohorts with schizophrenia symptomology with conservative
amino acid changes (26,27). All ﬁve were transmitted from a parent
with two variants, p.Val65Ile and p.Ala271Val, inherited from a
parent that was asymptomatic (26,27). Of the ATD variants iden-
tiﬁed, only the frameshift variants p.Thr268SfsX15 and
p.Ser34GlnfsX25 were reported to be pathogenic in ClinVar.
4. GRIN2B mutations in agonist-binding domain (ABD)
The NMDAR ABD is highly conserved across different subunits
and is shaped like a clamshell with two opposite halves of the bi-
lobed domain largely (but not perfectly) corresponding to the
S1 and S2 regions of the polypeptide chain (32,33). Glutamate
binding to the GluN2B ABD induces a cleft closure within the bi-
lobed ABD, triggering subsequent transition of NMDARs into an
open state. Thus far, all six variants identiﬁed in the S1 region are
missense de novo mutations in patients with ID, EE, and ASD
(12,13,16,24,34,54), whereas 4 of 13 variants in the S2 domain
produce a frameshift or introduce a stop codon. Eleven of twelve
variants in S2 are de novomutations in patients with mild to severe
ID, DD, ASD or cerebral visual impairment with or without epilepticfeatures (7,11e13,15,17,20,23,24,26,29,54). None of these S1 or S2
ABD mutations are found in the Exome Aggregation Consortium
(ExAC) dataset (35, Table 1, Fig. 1).
The de novo mutation p.Glu413Gly occurred in a female patient
with severe intellectual disability and behavioral anomalies (34).
The Glu413 residue in the GluN2B ABD resides in close proximity to
several key amino acid residues that make direct atomic contact
with the agonist glutamate. Substituting Glu413 with glycine is
predicted to disrupt the glutamate binding pocket. Consistent with
this prediction, p.Glu413Gly decreased glutamate potency by ~50
fold without altering glycine potency (34,54). Five additional de
novo mutations, p.Cys461Phe, p.Cys436Arg, p.Cys456Tyr,
p.Asp524Asn, and p.Arg540His were reported in the S1 domain of
patients with ID, ASD, and childhood onset epilepsy (12,13,16,54).
Cys461 resides in the highly conserved glutamate binding pocket
whereinmutations on conserved residues often produce changes in
receptor function. As expected for variation in this critical region,
p.Cys461Phe decreased glutamate potency (54). p.Arg540His is
found to produce a mild increase in glutamate and glycine potency,
with decreased Mg2þ block and elevated Ca2þ permeability (13,54),
all of which could increase excitatory drive in the absence of ho-
meostatic compensatory mechanisms and contribute to the pa-
tient's epileptic phenotype. The p.Cys456Tyr variant resulted in
mixed effects on glutamate and glycine potency and the
p.Cys436Arg variant appears to be poorly expressed (54).
Thirteen variants in the S2 ABD domain have been implicated in
largely the same neurodevelopmental phenotypes as observed for
S1. The de novo missense mutation, p.Arg682Cys, was found in a
male patient with moderate intellectual disability and behavioral
anomalies (7,29) and the study of agonist concentrationeresponse
curves revealed a slight increase in glycine potency (2-fold) and
glutamate potency (1.7-fold) (7,54). The p.Arg696His variant iden-
tiﬁed in a female patient with severe ID and DD with features of
autism also caused an increase in glutamate potency (~5 fold)
without altering glycine potency (54). Three frameshift variants
(c.2172-2A>G, c.2351-2A>G and c.2360-2A>G) and a mutation
introducing a stop codon (p.Gln711X) were reported that ultimately
produce truncated proteins (7,20,23,24). All of these individuals had
intellectual disability, and these GRIN2B alterations are expected to
have haploinsufﬁciency effects, indicating that GluN2B loss-of-
function likely contributes to intellectual disability and autism.
Although no functional studies exist for the frameshift mutations in
the ABD S2, it seems likely that protein that is made is either
degraded, not trafﬁcked to the cell surface, or is non-functional. It is
C. Hu et al. / Journal of Pharmacological Sciences 132 (2016) 115e121 119notable and consistent with these protein truncation variants that
many of the missense ABD variants, likewise, when expressed in
in vitro systems, show substantial reductions in cell surface NMDAR
expression (Table 1, 54). Multiple additional missense or nonsense
de novo mutations in the ABD S2 (p.Gln662Pro, p.Arg682Cys,
p.Thr685Pro, p.Pro687Arg, p.Gly689Ser, p.Arg696His, p.Met706Val,
and p.Gln711X) have been identiﬁed in patients with ID, DD, ASD,
cerebral visual impairment, and epilepsy with functional studies
reported in just two cases, both which increase glutamate potency
(11,12,15,17,21,26,54). Given these mutations reside in the ABD S2,
and the variant mutation introduces non-conservative amino acids
into the ABD, we anticipate many of these variants are likely to alter
GluN2B agonist potency and GluN2B subunit function and thusmay
contribute to the patient phenotype. As for the S1 domain, ClinVar
reports that several S2 variants are likely to be pathogenic, and
none of these S2 mutations have been reported in ExAC (35), sug-
gesting there is strong selective pressure against amino acid
changes in both the S1 and S2 ABD domains.
5. GRIN2B mutations in transmembrane domains (TM)
The NMDAR transmembrane domain (TM) is highly conserved
across all glutamate receptors and is connected to the ABD through
three short linkers (32). The TM domain is comprised of three
transmembrane helices M1, M3 and M4 as well as a reentrant loop
M2 that contributes to the formation of the cation-permeable pore.
The short linker region proceeding the M1 helix (pre-M1) is con-
nected to ABD S1, oriented parallel to the plane of the plasma
membrane, and in van der Waals contact with M3 and M4 in the
closed channel (36e38). The transmembrane region is the most
highly conserved region of the NMDA receptor family, and includes
key determinants of gating and ion permeation. Therefore, muta-
tions or alterations in the sequence of TMmight be deleterious and
thus result in neurodevelopmental phenotypes.
The missense de novo mutation p.Pro553Leu in the pre-M1
region was reported in a patient with intellectual disability
(9). Since the pre-M1 helix is positioned as a cuff of the external
surface of the NMDAR channel pore, the pre-M1 helix has
been suggested to be involved in channel gating. Although no
functional studies have been conducted, alterations in Pro553
might potentially inﬂuence channel gating, activation, deactiva-
tion, or desensitization time course. Additionally, a nonsense
variant (p.Trp559X) in the M1 region was identiﬁed in a patient
with intellectual disability and autism (24), and a missense de novo
mutation (p.Val558Ile) was reported in an individual with intel-
lectual disability (12). The premature stop codon almost certainly
creates a dysfunctional NMDAR protein product, particularly when
the mutation occurs at a position close to the translation initiation
site in the sequence. Several missense variants were identiﬁed in
the M1-M2 linker (p.Ala590Thr), the M2 domain (p.Trp607Cys,
p.Gly611Val, p.Asn615Ile, p.Val618Gly, p.Val620Met), the M2-M3
linker (p.Ser628Phe), or the M3 domain (p.Ala636Val, p.Ala636Pro,
p.Ala639Val), with the majority of these variants identiﬁed as de
novo in individuals with ID and features of epilepsy, ADHD, and
ASD (7,13,17,29,54). Two M2 missense mutations (p.Asn615Ile and
p.Val618Gly) enhance channel function by reducing Mg2þ block
and increasing Ca2þ permeability of the channel, two effects that
may contribute to the ID and West syndrome phenotype (13). The
majority of these variants are reported in ClinVar to be likely
pathogenic and none, except p.Ala590Thr, are in ExAC. Four de
novo missense mutations have been identiﬁed in the M4 domain
and a single de novo mutation in the S2-M4 linker in patients with
ID, DD, epilepsy or autism. However, functional studies for these
variants have not been reported (10,17,19,26,53). Similar to the ABD
variants, transmembrane domain variants are rare (<0.0008%),given these transmembrane domain mutations are not present in
ExAC.
6. GRIN2B mutations in carboxyl-terminal domain (CTD)
The NMDAR intracellular CTD is variable in sequence and con-
tains phosphorylation sites and short docking motifs for binding
proteins that play important roles in receptor trafﬁcking and
function (32). Currently, eleven missense variants (7,25e28), a
frameshift (14), and a single amino acid deletion (26) in GluN2B
CTD have been reported in patients with ID, ASD, and SCZ (See
Table 1). The missense mutations, p.Gly1026Ser, p.Ala1267Ser,
p.Thr1273Lys, or p.Met1339Val, in each of these patients was
inherited from a parent that did not present with the same
phenotype as their affected offspring. Three CTD variants,
p.Thr1228Met, p.Thr1273Lys, and p.Met1339Val were not associ-
ated with risk for ASD by burden analysis when compared to
controls, despite the ﬁnding that common synonymous variants
(SNPs) in the same region showed signiﬁcant risk for autism, sug-
gesting that ASD may be modiﬁed by genetic regulation or envi-
ronmental context for these GRIN2B variants (25). Ten of the
reported CTD variants (Table 1) have also been reported in ExAC
with varying minor allele frequencies, suggesting that selective
evolutionary pressure across CTD domain variations is lower in the
CTD than for TM and ABDs. Functional data for these CTD variants is
lacking, but mutations in the CTD region may cause trafﬁcking
defects due to the residence of several ER retention signals in this
region (39), which has been postulated to contribute to the
phenotype of the p.Lys1293Arg de novo variant identiﬁed in an AD
patient (28). In addition, regulation of NMDAR function through
post-translational modiﬁcation of the CTD is well known (32), and
could be altered by missense mutations at sites of or adjacent to
those subject to posttranslational modiﬁcation. Numerous scaf-
folding proteins and intracellular proteins interact with the GluN2B
CTD, including PDZ family proteins such as LIN7, PSD95, SAP97, and
SAP102, cytoskeletal protein a-actinin-2, scaffold protein RACK1,
and adaptor protein AP2 (40e48). Disrupting these interactions is
another means by which missense mutations or truncation muta-
tions could alter NMDAR localization or function.
7. Conclusion
The advent of whole exome/genome sequencing techniques
over the last 20 years has provided researcherswith unprecedented
data relating genomic variations to the various neuro-
developmental disorder phenotypes, including autism, intellectual
disability, epilepsy, and ADHD. These data have shown that the
GRIN2B gene has less variation in the healthy population than
normally expected, and is associated with epilepsy (49,50). Many of
the mutations in GRIN2B that are associated with neuro-
developmental disorders, such as intellectual disabilities, are loss-
of-function mutations resulting from frameshift, nonsense, or
missense mutations in key conserved residues. This early data
raises the possibility that mutations that reduce expression or
function of GluN2B may alter development of the central nervous
system and contribute to intellectual delay or disability, epilepsy
and autism. De novo missense mutations in critical TM and ABD
regions, or frameshift or nonsense mutations leading to truncated
proteins, were absent from SCZ patient cohorts. Rather, these co-
horts reveal missense mutations in the ATD or CTD domains where
ExAC allele frequencies trend higher and association with SCZ may
be variable or low (27), consistent with a lack of association be-
tween clozapine response and GRIN2B variants in a SCZ patient
population (51). Notably, the agonist binding domain of GluN2B
exhibits signiﬁcant intolerance to mutation based on absence of
C. Hu et al. / Journal of Pharmacological Sciences 132 (2016) 115e121120these variants in ExAC control exomes (Table 1, Fig. 1B). Further-
more, the ABD of GluN2B is less tolerant to variation than the
analogous regions of GluN2A (54). Identiﬁcation of a means of
tailoring precisionmedicine for this target patient populations with
GRIN2B variants will be challenging, since only 14% of the >60
published mutations in GRIN2B implicated in neurodevelopmental
phenotypes have complementary functional analysis reported.
Moreover, many of the functional studies are incomplete. In addi-
tion, there is only minimal information (5) about how GRIN2B
deletion, truncation or mutation might alter the developing ner-
vous system. It seems likely that compensatory mechanisms will
alter expression of other NMDAR subunits in the absence of func-
tional GluN2B. Furthermore, there are no FDA-approved com-
pounds known to enhance NMDAR function; only polyamines,
aminoglycosides, and neurosteroids, which show low-potency
GluN2B-selective potentiation (32,52). Thus, in order to exploit
precision medicine for this condition, the screening of FDA-
approved drug libraries for compounds that can rectify mutation-
associated functional changes is needed. Such screens would
likely assess parameters such as co-agonist potency, channel open
probability, receptor trafﬁcking and surface expression, receptor
desensitization, and the sensitivity of the receptor to known
endogenous channel modulators (e.g. Hþ, Mg2þ and Zn2þ). Identi-
fying candidate compounds that might rectify some aspects of
GluN2B hypofunctionwill provide a starting point for investigation
of these agents in model systems, which will ultimately help to
advance the future development of therapeutic strategies.
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